Methods for treating barrett's metaplasia and esophageal adenocarcinoma
AssigneeInterpace Diagnostics Corporation
InventorsEric Matthew Gayle Ellsworth, Sydney David Finkelstein, Sara Ann Jackson, Brendan Corcoran, Dennis Morgan Smith
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating Barrett's metaplasia and esophageal adenocarcinoma and methods for determining mutational load as a predictor of the risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma.
Claims11
1-56. (canceled)
A method for treating subject with a high risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma, the method comprising:
- determining mutational load as a predictor of the risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma in a subject, by:
- amplifying DNA sequences in microsatellite regions 1p (CMM1, Lmyc), 3p (VHL, OGG1), 5q (MCC, APC), 9p (CDKN2A, CDKN2B), 10q (PTEN, MXI1), 17p (TP53), 17q (NME1), 18q (DCC), and 21q, 22q (NF2) from a biological specimen from the subject;
- detecting mutations in the microsatellite regions of the amplified DNA sequences;
- categorizing clonality of each mutation, wherein categorizing clonality of each mutation comprises assigning one of three categories selected from the group consisting of no clonality, low clonality and high clonality, wherein high clonality is assigned where loss of heterozygosity is present in greater than about 75% of DNA analyzed, low clonality is assigned where loss of heterozygosity is present in about 50% to about 75% of DNA analyzed;
- and no clonality is assigned where loss of heterozygosity is present in less than about 50% of DNA analyzed;
- calculating a mutational load based on the sum of low and high clonality mutations;
- assigning the subject to a risk category to a high mutational load risk category when the subject has a mutational load greater than or equal to 1.75;
- and
- administering to the subject that is assigned to the high mutational load risk category at least one treatment modality selected from endoscopic mucosal resection, endoscopic submucosal dissection, a therapeutically effective amount of radiofrequency ablation, a therapeutically effective amount of cryoablation, or a therapeutically effective amount of photodynamic therapy.
A method for determining mutational load as a predictor of the risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma in a subject, the method comprising:
- amplifying DNA sequences from a biological specimen from the subject;
- detecting mutations in microsatellite regions of the amplified DNA sequences;
- categorizing clonality of each mutation;
- calculating a mutational load based on the sum of low and high clonality mutations;
- wherein DNA microsatellite instability at a single locus is defined as 0.75z1, and wherein DNA microsatellite instability at multiple loci is defined as 0.75z1+0.5z2, wherein z1 represent a single locus displaying DNA microsatellite instability and z2 is the number of loci displaying DNA microsatellite instability greater than 1 locus;
- wherein the score for low clonality is 0.5x, wherein x is the number of low clonality mutations and the score for high clonality is y, wherein y is the number of high clonality mutations;
- and wherein the overall mutational load is y+0.5x+0.75z1+0.5z2;
- comparing the mutational load with a series of pre-determined mutational load cut-offs defining risk categories;
- and
- assigning the subject to a risk category corresponding to the subject's mutational load, wherein each risk category is indicative of the risk of disease progression.
Dependencies are inferred from the claim text.